Severe pulmonary toxicity in patients with leiomyosarcoma after treatment with gemcitabine and docetaxel.
Veltkamp
Stephan A
SA
Division of Experimental Therapy, The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands. s.veltkamp@nki.nl
Meerum Terwogt
Jetske M
JM
van den Heuvel
Michel M
MM
van Boven
Hester H
HH
Schellens
Jan H M
JH
Rodenhuis
Sjoerd
S
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001132:Arm / Q000473:pathology*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D000077143:Docetaxel; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D007890:Leiomyosarcoma / Q000188:drug therapy* / Q000556:secondary; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology; D012128:Respiratory Distress Syndrome / Q000139:chemically induced* / Q000473:pathology; D012720:Severity of Illness Index; D043823:Taxoids / Q000008:administration & dosage; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome; D000093542:Gemcitabine
D043823:Taxoids; D003841:Deoxycytidine; D000077143:Docetaxel; D000093542:Gemcitabine